

References

I-127

1. Blinatumomab: A novel, bispecific, T-cell engaging antibody. *AM J Health Syst Pharm.* 2016;73(1):e6-e13.
2. Gokbuget N, Zugmaier G, Bargou R, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. 2017;102(4):e132-e135.
3. Von Stackelberg A, Locatelli F, Gore L, et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *Clin Oncol.* 2016;34(36):4381-4389.
4. Le Jeune C, Thomas X. Potential for bispecific T-cell engagers: Role of blinatumomab in acute lymphoblastic leukemia. *Drug Des, Devel Ther.* 2016;10:757-765.
5. Barley A, Lin VW, Katz A, Hu K. Estimating long-term survival of adults with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab using historical data. *Adv Ther.* 2017;34:148-155.
6. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase II, single-arm, multicenter study. 2017;35(16):1795-1802.
7. Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. 2016;34(36):4381-4389.
8. Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. *N Engl J Med.* 2017;376:836-847.
9. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. 2018;131(14):1522-1531.
10. Rambaldi A, Ribera JM, Kantarjian HM, et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. 2020;126(2):304-310.
11. Hijazi Y, Klinger M, Kratzer A, et al. Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-Hodgkin lymphoma. *Curr Clin Pharmacol.* 2018;13(1):55-64.

12. Topp MS, Stein AS, Gokbuget N, et al. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. *Cancer Med.* 2021;10(8):2601-2610.
13. Blinatumomab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 22, 2016.
14. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Blinatumomab.
15. Micromedex DrugDex Compendium®. 2022.
16. National Comprehensive Cancer Network (NCCN). Blinatumomab. NCCN Drug and Biologics Compendium®. 2022.
17. Blincyto (blinatumomab) for injection, for intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 02/2022.